Literature DB >> 6769453

Diazepam and N-desmethyldiazepam concentrations in saliva, plasma and CSF.

C Hallstrom, M H Lader.   

Abstract

1 Salivary and plasma diazepam and nordiazepam concentrations were measured in 51 paired samples from four experimental situations. In seven of the patients CSF samples were estimated. 2 Correlation of 0.89 (P less than 0.001) was observed between salivary and plasma diazepam and 0.81 (P less than 0.001) between salivary and plasma nordiazepam. 3 Mean salivary diazepam was 1.6% (+/- 0.3%) of the plasma diazepam. It was found to vary markedly in an acute dosage study. Mean salivary nordiazepam was 2.9% (+/- 1%) of the plasma measure and was dependent on salivary flow rate. 4 CSF diazepam was in equilibrium with unbound plasma diazepam and salivary diazepam. 5 Mean protein binding of diazepam in vitro was 99.3% with no variations as a function of concentration. 6 The results suggest salivary diazepam and nordiazepam measures to be of value in epidemiological studies. However, they do not predict accurately the plasma total or unbound drug concentration from a salivary sample in an individual.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6769453      PMCID: PMC1429988          DOI: 10.1111/j.1365-2125.1980.tb01059.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Cerebrospinal-fluid concentration of diazepam and its metabolites in man.

Authors:  J Kanto; L Kangas; T Siirtola
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975-04

2.  Elimination of antipyrine from saliva as a measure of metabolism in man.

Authors:  R M Welch; R L DeAngelis; M Wingfield; T W Farmer
Journal:  Clin Pharmacol Ther       Date:  1975-09       Impact factor: 6.875

3.  Plasma protein binding of chlorpromazine.

Authors:  S H Curry
Journal:  J Pharm Pharmacol       Date:  1970-03       Impact factor: 3.765

4.  Diazepam metabolism in normal man. II. Serum concentration and clinical effect after oral administration and cumulation.

Authors:  L Hillestad; T Hansen; H Melsom
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

5.  Estimation of pharmacokinetic parameters of lithium from saliva and urine.

Authors:  U Groth; W Prellwitz; E Jähnchen
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

6.  Plasma concentrations of diazepam and of its metabolite N-desmethyldiazepam in relation to anxiolytic effect.

Authors:  H H Dasberg; E van der Kleijn; J P Guelen; H M van Praag
Journal:  Clin Pharmacol Ther       Date:  1974-05       Impact factor: 6.875

7.  Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations.

Authors:  S A Kaplan; M L Jack; K Alexander; R E Weinfeld
Journal:  J Pharm Sci       Date:  1973-11       Impact factor: 3.534

Review 8.  The determination of some 1,4-benzodiazepines and their metabolites in body fluids. A review.

Authors:  J M Clifford; W F Smyth
Journal:  Analyst       Date:  1974-05       Impact factor: 4.616

9.  Diphenylhydantoin, phenobarbital, and primidone in saliva, plasma, and cerebrospinal fluid.

Authors:  D Schmidt; J Kupferberg
Journal:  Epilepsia       Date:  1975-12       Impact factor: 5.864

10.  Factors affecting antipyrine metabolism in West African villagers.

Authors:  H S Fraser; C J Bulpitt; C Kahn; G Mould; J C Mucklow; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

View more
  8 in total

Review 1.  Relationships between CSF drug concentrations, receptor binding characteristics, and pharmacokinetic and pharmacodynamic properties of selected 1,4-substituted benzodiazepines.

Authors:  W A Colburn; M L Jack
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 2.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

3.  CSF penetration and pharmacokinetics of midazolam.

Authors:  S Sjövall; J Kanto; J J Himberg; M Hovi-Viander; M Salo
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of cerebrospinal fluid.

Authors:  M Bonati; J Kanto; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

Review 5.  Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants.

Authors:  H Liu; M R Delgado
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

6.  Inhibition of recombinant L-type voltage-gated calcium channels by positive allosteric modulators of GABAA receptors.

Authors:  Damien E Earl; Elizabeth I Tietz
Journal:  J Pharmacol Exp Ther       Date:  2011-01-24       Impact factor: 4.030

Review 7.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

8.  Plasma diazepam and desmethyldiazepam concentrations during long-term diazepam therapy.

Authors:  D J Greenblatt; T P Laughren; M D Allen; J S Harmatz; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.